


HOME CONOMY

India needs to build effective innovation ecosystem: McKinsey & Company

PTI | Boston | Published: Jun 27 2014, 22:12 IST

entity collaboration on

building talent.





The report argues that India will need to rapidly address critical gaps to meet its potential. (Image: Thinkstock)

Related Articles

India needs to build an effective innovation ecosystem to realise its full







Parents, take note! Early life stress can leave lasting impacts on brain

June 30, 2014



Older sperm donors as good as young: study

June 30, 2014



Now India Inc asks for retro ruling to over-rule SC order

Fiat Chrysler SUV Jeep to enter India market

Indian rupee edges down tracking Asian pairs, shares eyed

Faster reforms by govt can revive economic growth in India, curb stagflation: Morgan Stanley potential in the field of research and development particularly in the biopharma and health sector, a report said today.

"In order to bridge the gap between the current state and desired future and to realise the huge potential of India in biopharma innovation will require building an effective innovation ecosystem," said the report titled 'Re-imagining India's role in delivering affordable biopharma innovation'.

The report prepared by McKinsey & Company on behalf of the USA India Chamber of Commerce argues that India will need to rapidly address critical gaps to meet its potential.

The report, released during the annual 'US India BioPharma & Hralthcare Summit', urges the new government to articulate the critical role that health, healthcare innovation can play in nation building and

keeping benefit to the patient, the first criteria for all actions.

Urging the new Indian government to fix and clarify relevant policies and regulations around clinical trials and intellectual property (IP), the report says that in the short mid-term, India should focus cross border and cross entity collaboration on building talent and infrastructure across clinical trials, IP training and basic research.


"Build infrastructure and training focus in areas of R&D such a biologics, certain India-critical TAs (eg diabetes), translational research and late stage clinical trials," the report said.

It also called on the Indian government to consider creating a task force, ideally of highly credible scientific leaders, who can objectively assess the situation, create a case for change and drive a national agenda of positive change.

Noting that the mood today in India is very positive after the formation of the new government, USA India Chamber of Commerce president, Karun Rishi, hoped that this would lead to the decisions that the industry has been seeking and talking about in the last few years.

"The positive sentiments need to be harnessed into policies for well being of citizens in general and making India a global hub of BioPharma innovation," he said at the meeting being attended by top corporarte executives from India and American pharma sectors, academicians and government officials.

"One fails to understand, India a nation of 1.3 billion people with one sixth of the world population has not been able to play a significant role in BioPharma innovation. The leadership in New Delhi should strive to make India a significant player and partner in the global drug discovery and



TODAY'S PAPER

- SAT order on Reliance Industries insider trading case today
- OMCs, sugar companies indulge in blame game on ethanol blending
- Budget may offer tax breaks to power firms
- Young, rich India gives birth to maternal care boutiques
- Procurement of 12 items meagre despite MSPs



 Narendra Modi disguise my way of paying him tribute, says Vidya Balan

Read

Commented

MOST POPULAR

2. Budget booster: Arun Jaitley may double

India needs to build effective innovation ecosystem: McKinsey & Company - Financial Express tax exemption limit development," Rishi said. Narendra Modi committed offence in wife's Arguing that regulatory institutions in India need to be strengthened to accomplish this objective, case, says court Rishi suggested that it is time the Office of the Drug Controller General of India is elevated to a **UGC** asks Delhi University to continue statutory autonomous body like Securities and Exchange Board of India. BMS for 2013-14 batch, as 3-yr course Apple Inc CEO Tim Cook outed as gay by India's Biotechnology and Science and Technology Secretary, K Vijaya Raghavan, said the new **CNBC** anchor government has identified seven thrust areas for itself in the next one year. This includes maternal and fetal development; drug discovery for tropical diseases; developing new **GALLERIES** vaccines; eliminating open defecation and waste treatment technology collaboration; sustainable food PERFORMANCE OF security and sustainability, and energy solutions to bio tech. Experts believe that India has an enormous potential in the biotechnology sector to become a USD 100 billion industry in the next decade. Core industries, Real **Box Office** Raghavan said India is today working towards creating an ecosystem of innovation and the Indian estate, Indian rupee, Collections: Holiday -Biotechnology is poised to provide solutions to the challenges that the country faces. **BSE Sensex, NSE** A Soldier Is Never Off Duty Nifty, Gold price on

June 30, 2014